Irritable Bowel Syndrome - Budesonide.

Suspended

• Registration Number: NL-OMON28758

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Suspended
• Sex: Not specified
• Target Recruitment: 32

Inclusion Criteria

Fulfilling Rome II criteria of IBS, 18-65 years of age, no other organic abnormalities explaining the complaints.

Exclusion Criteria

Severe comorbidity, pregnancy/lactation.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The effect of budesonide on the rectal sensitivity in IBS. Participants are treated with budesonide 3 dd 3 mg or placebo during eight weeks. To assess the rectal sensitivity a barostat investigation is performed before and after the treatment-period.

Secondary Outcome Measures

Name	Time	Method
The effect of budesonide on inflammation in rectal biopsy specimen and the effect of budesonide on IBS-symptoms.